Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTXHYV6)

• DTT Name: Voltage-gated L-type calcium channel (L-CaC) DTT Info
• Gene Name: L-CaC

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[1]
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[2]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[3]
Otilonium bromide	DM05968	Gastric motility disorder	DA21	Approved	[4]
Levamlodipine	DM92S6N	Hypertension	BA00-BA04	Phase 4	[5]

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[6]
Pinaverium bromide	DM7OSHC	Irritable bowel syndrome	DD91.0	Phase 3	[4]
MEM-1003	DMYZU6G	Bipolar disorder	6A60	Phase 2a	[7]
BAY-Y-5959	DMLO18H	Cardiovascular disease	BA00-BE2Z	Phase 2	[8]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[9]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Furnidipine	DME94QF	Nerve injury	ND56.4	Discontinued in Phase 3	[10]

20 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ajinomoto 1	DMHMVOI	Pain	MG30-MG3Z	Investigative	[2]
Ajinomoto 2	DMZE45V	Pain	MG30-MG3Z	Investigative	[2]
Ajinomoto 3	DMG12AE	Pain	MG30-MG3Z	Investigative	[2]
Bay K 8644	DMRWSGO	Discovery agent	N.A.	Investigative	[11]
Dihydropyridines	DM0W64U	Discovery agent	N.A.	Investigative	[12]
Euro-Celtique 1	DMO3AZ6	Pain	MG30-MG3Z	Investigative	[2]
Euro-Celtique 2	DMJH4BF	Pain	MG30-MG3Z	Investigative	[2]
Euro-Celtique 3	DM8VI3T	Pain	MG30-MG3Z	Investigative	[2]
Euro-Celtique 4	DMO4CEL	Pain	MG30-MG3Z	Investigative	[2]
Neuromed 2	DMSJ6T1	Pain	MG30-MG3Z	Investigative	[2]
Neuromed 5	DMXKT45	Pain	MG30-MG3Z	Investigative	[2]
Ono 1	DMSWI4D	Pain	MG30-MG3Z	Investigative	[2]
Ono 3	DMCG6H8	Pain	MG30-MG3Z	Investigative	[2]
Parke-Davis 1	DMVI8R2	Pain	MG30-MG3Z	Investigative	[2]
Parke-Davis 9	DMMQY42	Pain	MG30-MG3Z	Investigative	[2]
PD173212	DMRBKW6	Pain	MG30-MG3Z	Investigative	[2]
PD176078	DM6XHUZ	Pain	MG30-MG3Z	Investigative	[2]
S 202 791	DMGEHNX	Discovery agent	N.A.	Investigative	[11]
SQ32,910	DML6SIE	Discovery agent	N.A.	Investigative	[11]
[3H](-)devapamil	DM0KGHP	Discovery agent	N.A.	Investigative	[9]

References

• [1] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [2] Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [5] Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
• [6] N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
• [7] Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
• [8] Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.
• [9] Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
• [10] Q-type Ca2+ channels are located closer to secretory sites than L-type channels: functional evidence in chromaffin cells. Pflugers Arch. 1998 Mar;435(4):472-8.
• [11] Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96.
• [12] Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66.